Document:

EX-4.4

 Exhibit 4.4 
 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS CONVERTIBLE PROMISSORY NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”). THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. 

THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE
STATE OF CALIFORNIA OR ANY OTHER STATE AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SUCH SECURITIES IS EXEMPT FROM
QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE OR SUCH PROVISIONS OF THE CORPORATIONS CODE OF ANY SUCH OTHER STATE. THE RIGHTS OF THE HOLDER OF THIS CONVERTIBLE PROMISSORY NOTE ARE EXPRESSLY CONDITIONED UPON SUCH
QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 
  

			
	$            	 	 San Diego, California
 May 30, 2013

 CONATUS PHARMACEUTICALS INC. 

CONVERTIBLE PROMISSORY NOTE 
 CONATUS PHARMACEUTICALS INC., a Delaware corporation (the “Company”), for value received, hereby promises to pay to
                    , or its registered assigns (the “Holder”), the principal amount of
         Dollars ($         ) (the “Issue Price”), together with interest on the unpaid amount thereof in accordance with the terms
hereof, from the date hereof until paid or converted in accordance with the terms of this Convertible Promissory Note (this “Note”). This Note is one of a series of notes (the “Notes”) issued pursuant
to that certain Note and Warrant Purchase Agreement dated May 30, 2013 by and among the Company and the entities and persons listed on the Schedule of Investors thereto (the “Agreement”), and the Holder and the Company
shall be bound by all the terms, conditions and provisions of the Agreement. Capitalized terms used and not defined herein shall have the meanings ascribed to them in the Agreement. 

1. CONVERTIBLE PROMISSORY NOTE. 

1.1 INTEREST RATE. The rate of interest hereunder (“Interest Rate”) shall equal six
percent (6%) per annum, and shall be computed on the basis of a 365 day year for the actual number of days elapsed, provided that in no event shall the Interest Rate be less than the minimum rate of interest required in order to avoid the
imputation of interest for federal income tax purposes. 
 1.2 PAYMENT. Subject to the provisions of Sections 2
and 3 regarding conversion of this Note, the Issue Price of the Note plus all accrued but previously unpaid interest thereon shall become due and payable on the earlier of (i) any date on or after November 30, 2013 (the
“Maturity Date”) upon which the Requisite Majority demands payment, with such Maturity Date subject to extension pursuant to Section 3.1, and (ii) the occurrence of a Change of Control (as defined below). Payment
shall be made at the offices of the Holder, or such other place as the Holder shall have designated to the Company in writing, in lawful money of the United States of America. A “Change of Control” shall mean

  
 1 

 
(i) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, consolidation or merger
(whether or not the Company is a surviving entity after the merger, but, excluding any merger effected exclusively for the purpose of changing the domicile of the Company), or (ii) a sale or other disposition of all or substantially all of the
assets of the Company; unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale hold at least 50% of the voting power of the surviving or acquiring
entity. 
 1.3 PREPAYMENT. This Note may not be prepaid by the Company, in whole or in part, without the written
consent of the Requisite Majority. 
 1.4 EVENT OF DEFAULT. If there shall be any
Event of Default (as defined below), at the option and upon the declaration of the Holder of this Note and upon written notice to the Company (which election and notice shall not be required in the case of an Event of Default under
Section 1.4(c) or 1.4(d)), this Note shall accelerate and all principal and unpaid accrued interest shall become due and payable. The occurrence of any one or more of the following shall constitute an Event of Default: 

(a) The Company fails to pay timely any of the principal amount due under this Note on the date the same becomes due and payable or any
accrued interest or other amounts due under this Note on the date the same becomes due and payable; 
 (b) The Company
materially breaches any representation or warranty made by the Company under the Agreement, which breach has not been cured within ten (10) days of written notice thereof by the Holder; 

(c) The Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other
law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing; 

(d) An involuntary petition is filed against the Company (unless such petition is dismissed or discharged within sixty (60) days
under any bankruptcy statute now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company; or

 (e) The Company defaults under any other current or future debt obligation of the Company relating to indebtedness in excess
of $50,000 in the aggregate. 

  
 2 

 2. AUTOMATIC CONVERSION. 

2.1 AUTOMATIC CONVERSION UPON QUALIFIED IPO. In the event the Company
completes a Qualified IPO prior to the Maturity Date, the Issue Price of the Note plus all accrued and previously unpaid interest thereon shall be automatically converted into that number of fully paid and nonassessable shares of the Company’s
Common Stock as is equal to the Issue Price of the Note plus all accrued and previously unpaid interest thereon divided by the price per share that such shares are offered to the public in the Qualified IPO (the “IPO Per Share
Price”), rounded down to the nearest whole share. 
 2.2 AUTOMATIC CONVERSION
UPON PRIVATE PLACEMENT. In the event the Board and the Requisite Majority approve, after the date hereof and prior to the Maturity Date, any private placement of equity and/or debt securities of the
Company (the “Private Placement”) in lieu of a Qualified IPO, the Issue Price of the Note plus all accrued and previously unpaid interest thereon shall be automatically converted into (a) that number of fully paid and
nonassessable shares of the Company’s Preferred Stock or other equity securities sold in the Private Placement (the “New Equity Securities”) as is equal to the Issue Price of the Note plus all accrued and previously
unpaid interest thereon divided by the lowest price per share paid by investors for the New Equity Securities in the Private Placement (the “Per Share Price”), rounded down to the nearest whole share and/or (b) an
equivalent dollar amount of debt securities, as applicable (the “New Debt Securities” and, together with the New Equity Securities, the “New Securities”). The New Securities issued to the Holder upon
conversion of the Note in accordance with this Section 2.2 shall have the same rights, preferences and privileges as the New Securities purchased by the other investors in the Private Placement, and the Holder agrees to be bound by any
agreements related to the New Securities that such other investors enter into in connection with such Private Placement. The Holder shall have no right (other than the Holder’s right as a securityholder) to negotiate any of the terms or
conditions upon which the New Securities shall be issued, which negotiation shall be conducted solely among the Company and the purchasers of the New Securities.  
 2.3 CONVERSION PROCEDURE. Written notice of the Qualified IPO or Private Placement shall be delivered to the Holder of this Note at least three (3) days in advance of
the scheduled closing date of the Qualified IPO or Private Placement (the “Conversion Date”), at the address last shown on the records of the Company for the Holder or given by the Holder to the Company for the purpose of
notice (or, if no such address appears or is given, at the place where the principal executive office or residence of the Holder is located), notifying the Holder of the conversion to be effected, including confirming, if applicable, (i) the
IPO Per Share Price, (ii) the Per Share Price and (iii) the Conversion Date. The Note shall automatically convert on the Conversion Date without any further action by the Holder hereof. 

2.4 TERMINATION OF RIGHTS UPON CONVERSION. Any conversion of
this Note in accordance with Section 2.1 or Section 2.2 above shall be deemed effective on the Conversion Date, and, upon conversion of this Note, the Holder of this Note shall have no further rights under this Note, whether or not this
Note is surrendered. 

  
 3 

 2.5 DELIVERY OF DOCUMENTS
EVIDENCING OWNERSHIP. As promptly as practicable after any conversion of this Note and its surrender for cancellation by the Holder, the Company, at its expense, shall issue and deliver to the Holder of this Note one or
more certificates, account statements, debt instruments, or other documents evidencing the number of securities issuable to Holder upon any such conversion. 
 3. EXTENSION OF MATURITY DATE OR OPTIONAL CONVERSION. 

3.1 EXTENSION OF MATURITY DATE. In the event the Company does not complete a
Qualified IPO or Private Placement prior to the Maturity Date, upon the written consent of the Requisite Majority: (i) the Maturity Date may be extended to November 30, 2014 or (ii) the Issue Price of the Note plus all accrued
and previously unpaid interest thereon may be converted into shares of $0.0001 par value Series B Preferred Stock of the Company (the “Series B Preferred Stock”) in accordance with Section 3.2. 

3.2 OPTIONAL CONVERSION. If the Requisite Majority elects to convert the Note into Series B Preferred Stock
pursuant to Section 3.1, the Issue Price of the Note plus all accrued and previously unpaid interest thereon shall be automatically converted into that number of fully paid and nonassessable shares of Series B Preferred Stock as is equal to the
Issue Price plus all accrued and previously unpaid interest thereon divided by $0.90 (as adjusted for all stock splits, stock dividends, combinations, reclassifications, recapitalizations and reorganizations with respect to such shares), rounded
down to the nearest whole share. The shares of Series B Preferred Stock issued to the Holder upon conversion of the Note in accordance with this Section 3.2 shall have the same rights, preferences and privileges as the Series B Preferred Stock
then outstanding, and the Holder agrees to be bound by any agreements related to the Series B Preferred Stock that such other investors entered into in connection with such financing. 

4. MISCELLANEOUS. 
 4.1 LIMITATIONS ON DISPOSITION. The Holder agrees not to make any disposition of this Note or any securities issued upon conversion of this Note (the
“Securities”), unless and until (i) the transferee has agreed in writing for the benefit of the Company to be bound by this Section 4.1 and the other provisions of this Note as if such transferee were the original
Holder hereof, provided and to the extent such provisions are then applicable, and (ii) such transfer is in compliance with applicable securities laws. 
 4.2 TITLES AND SUBTITLES. The titles and subtitles used in this Note are for convenience only and are not to be considered in construing or interpreting this
Note. 
 4.3 NOTICES. All notices and other communications under this Note shall be in writing and shall be
deemed given upon receipt if delivered personally, or when sent if mailed by registered or certified mail (return receipt requested) or by reputable overnight express courier (charges prepaid) or transmitted by facsimile (with confirmation of
transmittal) to the party to be notified at the address indicated for such party on the signature page hereof, or at such other address as such party may designate by advance written notice to the other parties. 

  
 4 

 4.4 ATTORNEYS’ FEES. If any action at law or in equity is
necessary to enforce or interpret the terms of this Note, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and disbursements in addition to any other relief to which such party may be entitled. 

4.5 AMENDMENTS AND WAIVERS. This Note may be amended and the observance of any term of this
Note may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the Requisite Majority; provided, however, that the principal amount and interest rate of this
Note may be amended only with the written consent of the Holder of this Note. Any amendment or waiver effected in accordance with this Section 4.5 shall be binding upon the Holder of this Note (and of any securities into which this Note is
convertible), and each future holder of all such securities and the Company. 
 4.6 SEVERABILITY. If one or more
provisions of this Note are held to be unenforceable under applicable law, such provision shall be excluded from this Note and the balance of the Note shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms. 
 4.7 GOVERNING LAW. This Note (including any claim or controversy arising out of
or relating to this Note) shall be governed by and construed and enforced in accordance with the laws of the State of California, without giving effect to conflicts of laws principles that would result in the application of any law other than the
law of the State of California. 
 [SIGNATURE PAGE FOLLOWS] 

  
 5 

 This Note may be executed in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
 Date: May 30, 2013 

 

			
	CONATUS PHARMACEUTICALS INC.,
	a Delaware corporation
		
	By:	 	  

	Name:	 	Steven J. Mento, Ph.D.
	Title:	 	President and Chief Executive Officer

 
			
		
	Address:	 	4365 Executive Drive, Suite 200
		 	San Diego, California 92121

  

			
	ACKNOWLEDGED AND AGREED:
	
	INVESTOR
		
	By:	 	  

	Name:	 	  

	Title:	 	

			
		
	Address:EX-4.5

 Exhibit 4.5 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THESE SECURITIES ARE SUBJECT TO
RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. 
 THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA OR ANY OTHER STATE AND THE ISSUANCE OF SUCH
SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SUCH SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 2511, 25102 OR 25105 OF THE CALIFORNIA
CORPORATIONS CODE OR SUCH PROVISIONS OF THE CORPORATIONS CODE OF ANY SUCH OTHER STATE. THE RIGHTS OF THE HOLDER OF THIS WARRANT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 

Void after 

May 30, 2018 

WARRANT TO PURCHASE SHARES 
 OF SERIES B PREFERRED STOCK 
 of 

CONATUS PHARMACEUTICALS INC. 
 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 
 THIS CERTIFIES THAT,
for value received,                     , together with its permitted successors and assigns (“Holder”) is entitled, subject
to the terms set forth below, to subscribe for and purchase shares of $0.0001 par value Series B Preferred Stock (the “Series B Preferred Stock”) of CONATUS PHARMACEUTICALS
INC., a Delaware corporation (the “Company”), subject to adjustment as provided herein. This warrant and any warrant subsequently issued upon exchange or transfer hereof are hereinafter referred to
collectively as the “Warrant.” 
 This Warrant is subject to the following terms and conditions:

 1. Convertible Promissory Note; Potential Forfeiture. 

1.1 This Warrant is issued in connection with that certain Convertible Promissory Note dated May 30, 2013 (the
“Note”) by the Company in favor of Holder pursuant to that certain Note and Warrant Purchase Agreement dated May 30, 2013 by and among the Company and the entities and persons listed on the Schedule of Investors thereto
(the “Agreement”), and the Holder and the Company shall be bound by all the terms, conditions and provisions of the Agreement. All capitalized terms used but not defined in this Warrant shall have the meanings ascribed
thereto in the Note. 
 1.2 This Warrant is subject to forfeiture and cancellation as set forth in Section 2.2 of the
Agreement. 

  
 1 

 2. Exercise of Warrant. The terms and conditions upon which this Warrant may be
exercised, and the shares covered hereby may be purchased, are as follows: 
 2.1 Term. Subject to the terms hereof and
unless sooner terminated as provided below in Section 6.3, this Warrant may be exercised at any time after the date hereof, or from time to time, in whole or in part; provided, however, that in no event may this Warrant be exercised (the
“Exercise Date”) later than 5:00 p.m. (Pacific Time) on the close of business on May 30, 2018 (the “Exercise Period”). 
 2.2 Number of Series B Preferred Stock Shares. This Warrant may be exercised for
[            (        )] shares of Series B Preferred Stock, subject to adjustment as provided herein. 

2.3 Exercise Price. The “Exercise Price” shall be the lesser of $0.90 per share or the IPO Per Share
Price, subject to adjustment as provided herein. 
 2.4 Method of Exercise. Subject to the terms and conditions contained
herein and while this Warrant remains outstanding and exercisable, this Warrant is exercisable with respect to any or all of the shares of Series B Preferred Stock, at the option of Holder, upon surrender of this Warrant to the Company together with
(a) a duly completed (i) Notice of Exercise, in the form attached hereto as Exhibit A, or (ii) Net Issue Election Notice, in the form attached hereto as Exhibit B and (b) payment of an amount equal to the
Exercise Price multiplied by the number of shares of Series B Preferred Stock with respect to which this Warrant is being exercised as provided in Section 2.5 below. If Holder exercises this Warrant with respect to less than all of the shares
of Series B Preferred Stock represented by this Warrant, the Company shall cancel this Warrant upon the surrender thereof and shall execute and deliver to Holder a new Warrant for the balance of such shares of Series B Preferred Stock. 

2.5 Payment. Payment of the Exercise Price for the shares of Series B Preferred Stock with respect to which this Warrant is being
exercised by Holder shall be made, at the option of Holder, (a) by delivery of cash payable by wire transfer of immediately available funds, (b) by the delivery of a cashier’s check or certified check, (c) by net issue election
as set forth in Section 2.6 below, or (d) by any combination of (a) – (c). 
 2.6 Net Issue Election
Holder may elect to receive, without payment by Holder of any additional consideration, shares of Series B Preferred Stock equal to the value of the “spread” on the shares of Series B Preferred Stock or any portion thereof by the surrender
of the Warrant to the Company, together with a duly completed Net Issue Election Notice, in the form attached hereto as Exhibit B, at the principal office of the Company, in which event the Company shall issue to Holder such number of shares
of Series B Preferred Stock as is computed using the following formula, rounded down to the nearest whole share: 
 X = Y (A
– B) 
           A 

  
 2 

							
	Where:	  		  	X =	  	The number of shares of Series B Preferred Stock to be issued to Holder pursuant to the net issue election;
				
		  		  	Y =	  	The number of shares of Series B Preferred Stock in respect of which the net issue election is made;
				
		  		  	A =	  	The fair market value (as determined below) of one share of Series B Preferred Stock at the time the net issue election is made; and
				
		  		  	B =	  	The Exercise Price in effect under this Warrant as of the date of the net issue election.

 For purposes of this Section 2.6, the fair market value of one share of Series B Preferred Stock as of a particular
date shall be as determined in good faith by the Board of Directors of the Company. 
 3. Adjustment of Exercise Price and
Number of Shares. The Exercise Price and the number of shares of Series B Preferred Stock purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the happening of certain events as follows: 

3.1 Conversion of Series B Preferred Stock into Common Stock. Upon conversion of all of the issued and outstanding shares of the
Company’s Series B Preferred Stock into shares of the Company’s Common Stock (“Common Stock”), this Warrant shall be automatically exercisable only for such number of shares of Common Stock as Holder would have
received had this Warrant been exercised in full for the shares of Series B Preferred Stock and then converted into Common Stock on the date all issued and outstanding shares of the Company’s Preferred Stock converted into Common Stock. The
Exercise Price in effect immediately prior to such conversion shall, concurrently with the effectiveness of such conversion, be proportionally adjusted. Upon such conversion of the Preferred Stock into Common Stock, all references under this Warrant
to shares of Series B Preferred Stock shall be deemed references to Common Stock. 
 3.2 Split, Subdivision or
Combination. If the Company should at any time or from time to time fix a record date for (a) the effectuation of a split or subdivision of the outstanding shares of Series B Preferred Stock or (b) the determination of Holders of
Series B Preferred Stock entitled to receive a dividend or other distribution payable in additional shares of Series B Preferred Stock or other securities or rights convertible into, or entitling Holder thereof to receive directly or indirectly,
additional shares of Series B Preferred Stock (hereinafter referred to as the “Series B Equivalents”), without payment of any consideration by such holder for the additional shares of Series B Preferred Stock or Series B
Equivalents, then, as of such record date (or the date of such distribution, split or subdivision if no record date is fixed), the Exercise Price shall be appropriately decreased and the number of shares of Series B Preferred Stock which this
Warrant is exercisable for, if any, shall be appropriately increased in proportion to such increase of outstanding shares. Notwithstanding the foregoing, in any such case, the aggregate purchase price payable by Holder for the total number of shares
of Series B Preferred Stock (as adjusted) shall remain the same. 

  
 3 

 3.3 Combination of Shares. If the number of shares of Series B Preferred Stock
outstanding at any time after the date hereof is decreased by a combination of the outstanding shares Series B Preferred Stock, the Exercise Price shall be appropriately increased and the number of shares of Series B Preferred Stock for which this
Warrant is exercisable, if any, shall be appropriately decreased in proportion to such decrease in outstanding shares. Notwithstanding the foregoing, in any such case, the aggregate purchase price payable by Holder for the total number of shares of
Series B Preferred Stock (as adjusted) shall remain the same. 
 3.4 Reclassification or Reorganization. If the shares of
Series B Preferred Stock shall be changed into the same or different number of shares of any class or classes of stock, whether by capital reorganization, reclassification or otherwise (other than a subdivision, conversion or combination of shares
or stock dividend provided for in Sections 3.1, 3.2 and 3.3 above), then and in each such event Holder shall be entitled to receive upon the exercise of this Warrant the kind and amount of shares of stock and other securities and property receivable
upon such reorganization, reclassification or other change, to which a holder of the number of shares of Series B Preferred Stock (or any shares of stock or other securities which may be) issuable upon the exercise of this Warrant would have
received if this Warrant had been exercised immediately prior to such reorganization, reclassification or other change, all subject to further adjustment as provided herein. At the request of Holder, this Warrant will thereupon be cancelled and upon
its surrender to the Company, the Company will execute and deliver at its expense a new Warrant reflecting the foregoing adjustment, but otherwise identical to the replaced Warrant. 

3.5 Notice of Adjustments and Record Dates. The Company shall promptly notify Holder in writing of each adjustment or readjustment
of the Exercise Price hereunder and the number of shares of Series B Preferred Stock issuable upon the exercise of this Warrant. Such notice shall state the adjustment or readjustment and show in reasonable detail the facts on which that adjustment
or readjustment is based. In the event of any taking by the Company of a record of holders of shares of Series B Preferred Stock for the purpose of determining holders thereof who are entitled to receive any dividend or other distribution, the
Company shall notify Holder in writing of such record date at least twenty (20) days prior to the date specified therein. 

3.6 Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All shares of Series B Preferred Stock (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of a fractional share. If, after
aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from
multiplying the then current fair market value of a share of Series B Preferred Stock by such fraction. 
 3.7 Issue Tax.
The issuance of certificates for the shares of Series B Preferred Stock upon exercise of this Warrant shall be made without charge to Holder for any issuance tax in respect thereof provided that the Company shall not be required to pay any tax which
may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of Holder. 

  
 4 

 3.8 No Impairment. The Company shall not avoid or seek to avoid the observance or
performance of any of the terms to be observed or performed hereunder by the Company, but shall at all times in good faith assist in the carrying out of all the provisions of this Warrant. Without limiting the generality of the foregoing, the
Company shall take all such action as may be necessary or appropriate in order that all shares of Series B Preferred Stock as may be issued pursuant to the exercise of this Warrant shall, upon issuance, be duly and validly issued, fully paid and
nonassessable and free from all taxes, liens and charges with respect to the issue thereof. 
 4. Replacement of
Warrants. On receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an
indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of such Warrant, the Company at its expense shall execute and deliver to Holder, in lieu thereof, a
new Warrant of like tenor. 
 5. No Rights or Liability as a Stockholder. This Warrant does not entitle Holder hereof to
any voting rights or other rights as a stockholder of the Company. No provisions hereof, in the absence of affirmative action by Holder to purchase shares of Series B Preferred Stock, and no enumeration herein of the rights or privileges of Holder,
shall give rise to any liability of Holder as a shareholder of the Company. 
 6. Miscellaneous. 

6.1 Limitations on Disposition. Holder agrees not to make any disposition of this Warrant or any shares of Series B Preferred
Stock, unless and until (i) the transferee has agreed in writing for the benefit of the Company to be bound by this Section 6.1 and the other provisions of this Warrant as if such transferee were the original Holder hereof, provided and to
the extent such provisions are then applicable, and (ii) such transfer is in compliance with all applicable securities laws. 
 6.2 Early Termination. In the event of, at any time during the Exercise Period, any capital reorganization, or any reclassification of the capital stock of the Company (other than a change in par
value or from par value to no par value or no par value to par value or as a result of a stock dividend or subdivision, split-up or combination of shares), or the consolidation or merger of the Company with or into another corporation (other than a
merger solely to effect a reincorporation of the Company into another state), or the sale or other disposition of all or substantially all the properties and assets of the Company in its entirety to any other person, the Company shall provide to
Holder ten (10) days advance written notice of such public offering, reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets, and this Warrant shall terminate unless exercised prior to
the occurrence of such reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets. 
 6.3 Titles and Subtitles. The titles and subtitles used in this Warrant are for convenience only and are not to be considered in construing or interpreting this Warrant. 

  
 5 

 6.4 Notices. All notices and other communications under this Warrant shall be in
writing and shall be deemed given upon receipt if delivered personally, or when sent if mailed by registered or certified mail (return receipt requested) or by reputable overnight express courier (charges prepaid) or transmitted by facsimile (with
confirmation of transmittal) to the party to be notified at the address indicated for such party on the signature page hereof, or at such other address as such party may designate by advance written notice to the other parties. 

6.5 Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Warrant, the
prevailing party shall be entitled to reasonable attorneys’ fees, costs and disbursements in addition to any other relief to which such party may be entitled. 
 6.6 Amendments and Waivers. This Warrant may be amended and the observance of any other term of this Warrant may be waived (either generally or in a particular instance and either retroactively or
prospectively), with the written consent of the Company and the holders of at least 75% in interest of the shares issuable upon exercise of all then-outstanding Warrants. Any amendment or waiver effected in accordance with this Section 6.6
shall be binding upon Holder of this Warrant (and of any shares of Series B Preferred Stock into which this Warrant is exercisable), and each future holder of all such securities and the Company. 

6.7 Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law, such provision
shall be excluded from this Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

6.8 Governing Law. This Warrant shall be governed by and construed and enforced in accordance with the laws of the State of
California, without giving effect to its conflicts of laws principles. 
 [SIGNATURE PAGE
FOLLOWS] 

  
 6 

 This Warrant may be executed in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
  

							
	Date: May 30, 2013	 		 	CONATUS PHARMACEUTICALS INC.,
		 		 	a Delaware corporation
				
		 		 	By:	 	  

		 		 	Name:	 	Steven J. Mento, Ph.D.
		 		 	Title:	 	President and Chief Executive Officer
				
		 		 	Address:	 	4365 Executive Drive, Suite 200
		 		 		 	San Diego, California 92121

  

			
	ACKNOWLEDGED AND AGREED:
	
	INVESTOR
		
	By:	 	  

	Name:	 	  

	Title:	 	
		
	Address:	 	  

		 	  

 [SIGNATURE PAGE TO WARRANT TO PURCHASE 

SHARES OF SERIES B PREFERRED STOCK] 

 EXHIBIT A 
 FORM OF NOTICE OF EXERCISE 
 The undersigned, the holder of the within Warrant,
hereby irrevocably elects to exercise this Warrant for, and to purchase thereunder,                      shares of Series B Preferred Stock
(as defined in the attached Warrant)* of CONATUS PHARMACEUTICALS INC., a Delaware corporation and herewith makes payment of $        therefor and
requests that the certificates for such shares be issued in the name of, and delivered to,                     , federal taxpayer
identification number                     , whose address is
                                         
                               . 

In exercising this Warrant, the undersigned hereby confirms and acknowledges that the
                     shares of Series B Preferred Stock (as defined in the attached Warrant) are being acquired solely for the account of the
undersigned and not as a nominee for any other party, and for investment, and the undersigned will not offer, sell or otherwise dispose of any such shares of Series B Preferred Stock except under circumstances that will not result in a violation of
the Securities Act of 1933, as amended, or any state securities laws. 
 Please issue a new Warrant for the unexercised portion
of the attached Warrant in the name of, and delivered to,                     , federal taxpayer identification number
                    , whose address is
                                         
                                         
  . 

Dated:                     

 

	
	  

	(Signature must conform to name of holder
	as specified on the face of the Warrant)

  

	*	Insert here the number of shares as to which the Warrant is being exercised. 

 EXHIBIT B 
 FORM OF NET ISSUE ELECTION NOTICE 
 (To be signed only on net issue exercise of the
Warrant) 
 The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise this Warrant with respect
to                      shares of Series B Preferred Stock (as defined in the attached Warrant) of CONATUS
PHARMACEUTICALS INC., a Delaware corporation, pursuant to the net issue election provisions set forth in Section 2.6 of the Warrant and requests that the certificates for the number of shares of Series B
Preferred Stock issuable pursuant to said Section 2.6 after application of the net issue election formula to such shares of Series B Preferred Stock be issued in the name of, and delivered to,
                                    , federal taxpayer
identification number                     , whose address is
                                         
                               . 

In exercising this Warrant, the undersigned hereby confirms and acknowledges that the shares of Series B Preferred Stock are being
acquired solely for the account of the undersigned and not as a nominee for any other party, and for investment, and the undersigned will not offer, sell or otherwise dispose of any such shares of Series B Preferred Stock except under circumstances
that will not result in a violation of the Securities Act of 1933, as amended, or any state securities laws. 
 Please issue a
new Warrant for the unexercised portion of the attached Warrant in the name of, and delivered to,                     , federal taxpayer
identification number                     , whose address is
                                         
                                         
  . 

Dated:                     

 

	
	  

	(Signature must conform to name of holder
	as specified on the face of the Warrant)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]